Ergothioneine

Cardiovascular is ergothioneine's strongest case at 6.5/10 because the observational signal is unusually consistent. Smith 2020 followed 3,236 adults for a median 21.4 years and found each 1 SD higher plasma ergothioneine tracked with a coronary-disease hazard ratio of 0.85 and a cardiovascular-mortality hazard ratio of 0.79. Mechanistically, ergothioneine protects vascular endothelium from oxidative and hyperglycemic stress. The score stays in worth-trying rather than higher because association is not causation: no cardiovascular outcome trial of ergothioneine supplementation exists yet, so the honest move is to treat it as a promising adjunct and track your own lipids and inflammation.

Antioxidant capacity earns 6.5/10, the use case where mechanism is best established. Cheah 2017 gave healthy adults pure ergothioneine at 5 to 25 mg and confirmed it is avidly absorbed, retained with under 4% urinary loss, and concentrates in red blood cells and tissues prone to oxidative stress. Unlike most antioxidants, the body built a dedicated OCTN1 transporter for it, which argues for a real physiological role. The cap below top-band reflects that biomarker movement is not the same as proven clinical benefit, the exact caution this report applies throughout: define one oxidative-stress marker and judge ergothioneine against it.

Longevity lands at 6.0/10 on the strength of the framing and the cohort data, not on lifespan trials, which do not exist in humans. Beelman 2020 argues ergothioneine is a longevity vitamin under-supplied by the American diet, building on Bruce Ames's triage theory in Ames 2018. Blood levels decline after age 60 and low levels track with mortality, frailty, and neurodegeneration. That is a coherent and compelling story, but it is correlational. Ergothioneine is most defensible here for people who eat few mushrooms and want a low-risk hedge while the interventional evidence matures.

Neuroprotection scores 6.0/10 because the signal is consistent across observational and small interventional work. Cheah 2016 found elderly adults with mild cognitive impairment had significantly lower plasma ergothioneine than controls, and Hatano 2016 reported lower serum levels in Parkinson's disease. The Yau 2024 pilot RCT in 19 people with mild cognitive impairment saw stabilized neurofilament light chain, a neurodegeneration marker, in the treated group. The honest limit is sample size: these are tiny, early studies, so this is a watch-and-track use case, not a proven therapy.

Healthspan earns 6.0/10 because ergothioneine touches several aging-related systems at once without a clear downside. The same blood-level associations that support cardiovascular and cognitive cases also link low ergothioneine to frailty in Kondoh 2022, which found it among antioxidation-related metabolites that decline as people become frail. Tissue retention means a steady internal pool rather than a spike-and-crash. The score stays mid-band because the evidence is the breadth of associations, not depth of outcome proof. Ergothioneine fits a healthspan stack as a cheap, very safe foundational antioxidant for people willing to play a long game.

Cognition and focus reach 5.5/10 on early, mixed interventional data. Zajac 2025, the largest human trial at 147 older adults with subjective memory complaints, found dose-dependent gains in subjective prospective memory and sleep initiation at 25 mg/day over 16 weeks, but an early composite-memory gain did not persist versus placebo. This trial was industry-sponsored, which warrants an evidence-confidence trim. Combined with Yau 2024, the picture is encouraging but unsettled. Treat any focus benefit as plausible and worth tracking with a daily clarity check, not as a reliable nootropic effect.

Anti-inflammatory support scores 5.5/10. The mechanism is sound: ergothioneine dampens reactive oxygen species and has reduced inflammatory markers in cell and animal models, and the cardiovascular protection seen in Smith 2020 is partly attributed to anti-inflammatory and anti-atherogenic activity. Human inflammation-endpoint trials are limited, though, so the score sits just above neutral. The practical approach is to set a baseline inflammation marker such as hs-CRP before starting and judge ergothioneine against that one number rather than crediting the mechanism alone.

Mitochondrial support earns 5.5/10 because ergothioneine concentrates inside mitochondria, one of the few antioxidants that reliably does so via active transport, as detailed in Cheah 2012. That positions it to buffer the oxidative byproducts of energy production at the source. The honest limitation is that mitochondrial localization is a mechanism, not a measured human functional outcome; there is no human trial showing improved mitochondrial function from supplementation. The score reflects strong mechanistic plausibility tempered by absent clinical endpoints, the same discipline applied across this report.

Geriatric use earns 5.5/10 because aging is exactly where the associations cluster. Blood ergothioneine declines after age 60 per Cheah 2016, and low levels track with frailty in Kondoh 2022 and with cognitive decline and mortality across cohorts. That makes older adults with low mushroom intake the single best-fit population for a low-risk antioxidant hedge. The score stays mid-band rather than higher because the evidence remains correlational: there is no outcome trial in older adults showing that restoring ergothioneine changes the trajectory, so track a relevant marker and judge it personally.

Immune function sits at neutral 5.0/10. Ergothioneine accumulates in immune cells and the mushrooms that supply it carry beta-glucans with their own immune activity, but direct human immune-outcome trials of isolated ergothioneine are essentially absent. The mortality and frailty associations in Kondoh 2022 are suggestive of broad resilience rather than a specific immune effect. This is a mechanism-and-association use case with no direct clinical proof, so neutral is the honest placement here.

Memory sits at a neutral 5.0/10 on early, mixed interventional data. The Yau 2024 pilot in 19 people with mild cognitive impairment found improved verbal learning in the treated group, and Zajac 2025 reported gains in subjective prospective memory at 25 mg per day. But the larger trial's objective composite-memory advantage did not hold versus placebo, and it was industry-sponsored, which warrants restraint. So the memory case is genuinely promising yet unproven; treat any benefit as plausible and worth tracking with a daily recall check rather than a reliable effect.